Exponential Biotherapies Inc.   Report issue

For profit Phase 1 Phase 2
Founded: The Hague Netherlands (1993)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2015
NCT02629874
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2016

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (1)

alanyl-glutaminyl-glycyl-valine (2 trials)

Drugs in Phase 1 Trials (1)

endotoxin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Endotoxemia (Phase 1)

Systemic Inflammatory Response Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2